CONMED to exit gastroenterology product lines as part of portfolio shift

CONMED Corp. announced it plans to exit its gastroenterology product lines as part of a broader effort to focus on the company’s core businesses, which include minimally invasive, robotic and laparoscopic surgery, smoke evacuation and orthopedic soft tissue repair.

“Today’s announcement reflects a positive step in our strategic portfolio review and our commitment to focus on areas where CONMED can lead in innovation and deliver the greatest impact—minimally invasive surgery, smoke evacuation, and orthopedic soft tissue repair,” said Patrick J. Beyer, CONMED’s president and CEO, in a statement. “By concentrating our resources on our core growth platforms, we are positioning CONMED for long-term success and continued leadership in surgical innovation. We are proud of the contributions our gastroenterology team has made to advancing patient care and supporting clinicians over the years, and we thank them for their dedication and impact on the business.”

The decision includes winding down its distribution agreement with W. L. Gore & Associates, Inc., under which CONMED has held exclusive U.S. and Canadian distribution rights for the Gore VIABIL biliary stent. The company had previously disclosed in its most recent 10-Q filing that it would not renew the agreement beyond Dec. 31, 2026, but said it has now elected to accelerate that timeline following a strategic review. The agreement will conclude effective Jan. 1, 2026. Financial terms were not disclosed.

CONMED said its gastroenterology product lines are expected to generate between $90 million and $95 million in revenue in 2025, with gross margins of about 45%. The company projects earnings-per-share dilution of 45 to 55 cents in 2026 as a result of the exit.

The move is expected to improve CONMED’s consolidated gross margin profile by about 80 basis points once the exit is complete. Proceeds from the Gore transaction will be used for general corporate purposes, including strategic investments, debt reduction and share repurchases, the company said.

CONMED reaffirmed its 2025 revenue guidance of $1.365 billion to $1.372 billion and adjusted earnings-per-share guidance of $4.48 to $4.53, noting it does not expect a material impact on next year’s financial results. The company plans to provide full 2026 guidance on its fourth-quarter 2025 earnings call.